API effectively alleviates CCl4-and bile duct ligation (BDL)-induced liver fibrosis by reducing liver enzyme levels, inhibiting ECM production, and regulating the balance between matrix metalloproteinase 2 (MMP2) and tissue inhibitors of metalloproteinase 1 (TIMP1) (Ji et al., 2021). The gene discussed is MMP2; the disease is Hepatic fibrosis.